Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play a pivotal role in managing type 2 diabetes mellitus (T2DM), obesity, and other conditions, with proven benefits including, but not limited to, weight loss, glycemic control, and cardiovascular protection. However, their implications for arthritis are still debatable. GLP-1RAs may reduce systemic inflammation, alleviate joint stress through overall weight loss, and exhibit chondroprotective effects. Nevertheless, concerns such as augmented gout flares, joint pain, and indefinite long-term outcomes temper their promise. This editorial highlights the dual nature of GLP-1RAs in arthritis, presenting them as both potential benefits and risks, contingent upon the specific arthritis subtype and individual patient profiles.